High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy

Takuma Kagami; Mihoko Yamade; Takahiro Suzuki; Takahiro Uotani; Shinya Tani; Yasushi Hamaya; Moriya Iwaizumi; Satoshi Osawa; Ken Sugimoto; Satoshi Baba; Haruhiko Sugimura; Hiroaki Miyajima; Takahisa Furuta

doi:10.18632/oncotarget.26172

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy

Takuma Kagami _, Mihoko Yamade, Takahiro Suzuki, Takahiro Uotani, Shinya Tani, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Satoshi Baba, Haruhiko Sugimura, Hiroaki Miyajima and Takahisa Furuta

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:34876-34888. https://doi.org/10.18632/oncotarget.26172

Metrics: PDF 1564 views | HTML 2248 views | ?

Abstract

Takuma Kagami1, Mihoko Yamade1, Takahiro Suzuki1, Takahiro Uotani1, Shinya Tani2, Yasushi Hamaya1, Moriya Iwaizumi3, Satoshi Osawa2, Ken Sugimoto1, Satoshi Baba4, Haruhiko Sugimura5, Hiroaki Miyajima1 and Takahisa Furuta6

1First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

2Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

3Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

4Department of Diagnostic Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan

5Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan

6Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Japan

Correspondence to:

Takuma Kagami, email: [email protected]

Keywords: cancer stem-like cell; CD44v8-10; esophageal cancer; chemoradiotherapy; sulfasalazine

Received: July 09, 2018 Accepted: September 13, 2018 Published: October 09, 2018

ABSTRACT

Background: Strong reactive oxygen species (ROS) suppression in cancer stem-like cell components in various solid tumors is associated with therapeutic resistance. In this study, we investigated the influence of CD44v8-10 expression on the overall survival of esophageal squamous cell carcinoma (E-SCC) patients after definitive chemoradiotherapy (dCRT) and on radio-sensitivities of E-SCC cell lines treated with or without sulfasalazine, a CD44v8-10-xCT-GSH axis inhibitor.

Methods: Seventy-three patients with E-SCC who received dCRT were examined retrospectively. CD44v8-10 expression was analyzed immunohistochemically using paraffin-blocked pre-dCRT biopsy specimens obtained by esophagoscopy and was expressed as a histo-score (H-score). The relationship between the H-score and overall survival was analyzed. From human E-SCC cell lines (T.T, T.Tn, or Kyse-3650), we collected CD44v8-10^High and CD44v8-10^Low subpopulations using a cell sorter. Water-soluble tetrazolium salt-8 (WST), glutathione-SH (GSH) and ROS assays were performed to compare the effect of sulfasalazine on the radio-sensitivities of these subpopulations in T.Tn and Kyse-3650.

Results: High CD44v8-10 expression was independently associated with poor prognosis in E-SCC patients treated with dCRT (hazard ratio = 2.906, 95% CI = 1.277–6.611, p = 0.011). In CD44v8-10^High cells of each cell line, sulfasalazine decreased cellular GSH levels, resulting in increased radiation-induced ROS and reduced cell viability. In contrast, sulfasalazine had no significant effects in CD44v8-10^Low cells.

Conclusion: High CD44v8-10 expression was an independent prognostic factor in E-SCC patients treated with dCRT. CD44v8-10-xCT-GSH axis inhibition sensitized CD44v8-10^High E-SCC cells to ROS-inducing treatments such as radiotherapy. Targeting CD44v8-10-xCT-GSH axis may improve the prognosis of post-dCRT E-SCC patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26172

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy

Abstract